Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Marleen Kok|Nature Medicine|2019Cited by 878
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023Giuseppe Curigliano, Marleen Kok, B. Xu et al.|Annals of Oncology|2023Cited by 218
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Clinical Cancer Research|2025Cited by 1
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Federica Miglietta, Maria Vittoria Dieci, Claudio Vernieri et al.|Journal of Clinical Oncology|2024Cited by 1
Supplementary Table S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Unknown|2025Cited by 0